Pulse Biosciences Q2 FY26 net loss widens to $24.66 million; revenue swings to $434,000
Reuters2026/08/06 20:35- Pulse Biosciences posted Q2 GAAP net loss of USD 24.7 million, widening from USD 19.2 million a year earlier; GAAP loss per share widened to USD 0.36.
- Revenue was USD 434,000, versus no revenue a year earlier, as it stayed in a controlled commercial launch focused on market development.
- GAAP costs and expenses rose to USD 25.7 million from USD 20.3 million, driven by higher clinical-program investment and compensation-related spend.
- Cash and cash equivalents climbed to USD 101.6 million at June 30 from USD 68.3 million at March 31, following USD 46.8 million net ATM proceeds.
- NANOPULSE-AF enrollment topped 82 evaluable patients, with completion targeted for early Q4; the company is progressing toward a 2H 2026 CE Mark submission.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pons: $20.93 million has been paid to token creators over the past 47 days
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
Crypto prices
More
